RPTX

Repare Therapeutics Inc. (RPTX) | Rumor.io

Repare Therapeutics

RPTX

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)91%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about RPTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% 0

Dec 25

Repare Therapeutics' Polθ inhibitor, RP-3467, has been acquired by Gilead Sciences for up to $30 million.
Repare Therapeutics' stock price has reached a new high at $2.55 with a significant increase in volume at 15.9M.
The company is a high-risk, high-reward research-driven stock with significant volatility, suitable for investors with a long-term perspective and a willingness to wait for key evidence to emerge.

Generated by AI

Sentiment

Of the messages about RPTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	95.48% +27.42
Bearish	—	—	—	4.52% -27.42

Bullish· Dec 24

Repare Therapeutics Inc. ($RPTX) has a potential CVR (contingent value right) that could significantly increase its value, with some analysts predicting a target price of $11-$13.
The company's recent breakeven revenue and cash inflow, combined with its high relative strength, suggest a strong financial position.
The acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for up to $30 million in total consideration is expected to have a positive impact on $RPTX's stock price, with some analysts predicting a price of $4.00 or higher.

Bearish· Dec 13

$RPTX's price target was cut by Stifel from $9 to $4, indicating a significant decrease in potential upside.
Repare Therapeutics' management is being criticized for their handling of the company, with some accusing them of being "scumbags".
The company's cash position is a concern, with some traders suggesting that it may not have enough money to last 1.5 years, increasing the likelihood of a further price drop.

Generated by AI

Topics

Of the messages about RPTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	0%	0%	0%	1.64%
Announcements	100%	100%	100%	85.63%
Controversies	0%	0%	0%	3.29%
Earnings	0%	0%	0%	0.41%
Macro	0%	0%	0%	0.41%
Technical Analysis	0%	0%	0%	8.62%

Announcements· Dec 24

Repare Therapeutics Inc. ($RPTX) has announced the acquisition of its Polθ ATPase inhibitor, RP-3467, by Gilead Sciences ($GILD) for up to $30 million in total consideration.
The deal includes a $25 million upfront payment and up to $5 million tied to the completion of specific technology transfer activities, which has boosted Repare's cash balance and increased the estimated cash payout to shareholders in the Xeno acquisition to about $2.20 per share.
Repare's Polθ ATPase inhibitor, RP-3467, is a promising cancer treatment targeting BRCA mutations, and the acquisition is seen as a strategic fit between Repare's asset and Gilead's oncology R&D capabilities.

Technical Analysis· Jun 2

$RPTX has a higher low setup with a beautiful trend line and a top resistance at $13.
The stock is approaching a golden cross, which could lead to a significant price increase.
$RPTX has broken above $13 and is setting up for a potential GAP UP, with resistance levels near $11.80, $12.25, and $13.20.

Generated by AI

Community

Of the messages about RPTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	40.71%
Newcomers	—	—	—	59.29%

Regulars· Dec 24

Repare Therapeutics Inc. has sold its Polθ ATPase inhibitor RP-3467 to Gilead Sciences for up to $30 million in total consideration.
The acquisition marks the third major transaction for Repare Therapeutics this year, following a portfolio transaction and a definitive arrangement agreement with XenoTherapeutics.
The sale of RP-3467 is expected to provide a significant boost to Repare Therapeutics' stock price, with the stock closing at around $2.20 after the announcement.

Newcomers· Dec 24

$RPTX, a biotech company, has acquired a Polθ ATPase inhibitor, RP-3467, by Gilead Sciences for up to $30 million.
The acquisition is a significant development for Repare Therapeutics, with many speculating about its potential impact on the company's future.
Newcomers to the asset are focusing on the prospects of other Repare Therapeutics' treatments, such as camonsertib/lunresertib and RP-1664, in comparison to the acquired RP-3467.

Generated by AI

Also Discussed

Investors talking about RPTX also mention

#	Name	Attention
1	Bicycle Therapeutics plc - ADRBCYC	0%0
2	ImageneBio, Inc.IKNA	0%0
3	Zymeworks Inc.ZYME	0%0
4	PMV Pharmaceuticals, Inc.PMVP	0%0
5	Caribou Biosciences, Inc.CRBU	0%0
6	DAWN - Day One Biopharmaceuticals, Inc.	——
7	908 Devices Inc.MASS	0%0
8	ALX Oncology Holdings Inc.ALXO	0%0
9	BioAtla Inc.BCAB	0%new
10	Beam Therapeutics IncBEAM	0.02%+0.02